Substance Withdrawal Syndrome
Conditions
Brief summary
In 2019, around 27 million people worldwide, corresponding to 0.5% of the adult population, have used amphetamine-type stimulants (ATS). More than one-third of these 27 million users of ATS were in East and South-East Asia. ATS are a group of synthetic psychostimulants including methamphetamine, amphetamine, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and related substances. Although the biology underlying amphetamine withdrawal syndrome is not fully understood, amphetamine has been shown to produce long-lasting reductions in neuronal expression of dopamine neuronal markers. Abuse of these synthetic psychostimulants can lead to drug addiction, and subsequent withdrawal can cause a series of mental symptoms, such as anxiety, depression, confusion, insomnia, mood disturbances, cognitive impairments, and delusions. Some studies have shown two clear stages of ATS withdrawal syndrome: an acute phase lasting 7-10 days, and a subacute phase lasting a further 2 weeks or more, which is termed called Protracted amphetamine abstinence syndrome (PAAS). The relevant literature has indicated that the majority of patients with ATS withdrawal disorders can experience depression, cognitive impairments, insomnia, and anxiety, especially during the PAAS stage. These symptoms may affect the treatment and finally lead to a relapse. Nowadays, pharmacological therapies are mostly symptom-targeted and show an ungratified effectiveness for amphetamine-type drugs. There is no a medication approved by Food and Drug Administration for use in the treatment of methamphetamine addiction. Therefore, the treatment of PAAS is essential for the treatment of ATS use disorders. Traditional Chinese medicine (TCM), especially acupuncture, is effective in the treatment of withdrawal symptoms with few side effects. research on acupuncture detoxification originates from the treatment of opioid drug withdrawal. Studies have shown that acupuncture has high efficacy in the treatment of protracted abstinence symptoms after heroin addiction. This study hypothesizes that acupuncture has the same mechanism of action in the treatment of PAAS as in the treatment of protracted opioid abstinence syndrome. Therefore, investigators have designed a real-world-based pragmatic randomized controlled trial (pRCT) to determine the effectiveness of acupuncture in the treatment of PAAS and provide support for clinical decision-making. Investigators conduct a pragmatic randomized controlled trials(pRCT) to observe the effect of acupuncture in a larger sample. It combines the advantages of randomization and real-world data, and the results can provide the best real-world evidence for the assessment of intervention effects or comparative effects.
Interventions
OTHERElectro-Acupuncture
Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
Sponsors
Chengdu University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients meet the diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (21); * A urine test for methamphetamine is negative. * 18-60 years old, male or female, conscious, no aphasia, or mental retardation, primary school education or above, and able to understand the contents of the scales and cooperate with treatment; * Did not participate in other clinical trials within 3 months; * Signed the informed consent from.
Exclusion criteria
* Local trauma or infected persons who have received EA; * Can' not tolerate EA, EA treatment, or allergic to EA needles; * Pregnant or breastfeeding women; * Serious disorders of the heart, liver, or kidney, or suicidal tendencies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Amphetamine Cessation Symptom Assessment | Change from baseline Amphetamine Cessation Symptom Assessment scores at 1 month. | It consists of three subscales, namely, anxiety and mood, fatigue, and craving. Items are scored on a five-point scale ranging from 0 to 4 with higher scores representing more severe Amphetamine Cessation Symptom |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analog Scale | Change from baseline Visual Analog Scale scores at 1 month. | Determining the craving for amphetamine.The scores is from 0 to 10, and the higher scores means the more craving for amphetamine. |
| Hamilton Depression Scale | Change from baseline Hamilton Depression Scale scores at 1 month. | Assessment for depression.And the interpretation of HAMD scores is as follows: \<7, no depression; 7-17, mild depression; 17-24, moderate depression; and \>24, severe depression. |
| Hamilton Anxiety Scale | Change from baseline Hamilton Anxiety Scale scores at 1 month. | Assessment for anxiety. And the interpretation of HAMA scores is as follows: \<7, no anxiety;7-14, mild anxiety; 14-20, moderate anxiety; 21-28, severe anxiety; and \>29, extremely severe anxiety. |
| Pittsburgh Sleep Quality Index | Change from baseline Pittsburgh Sleep Quality Index scores at 1 month. | The scores are from 0 to 21.Higher scores reflect worse sleep quality. |
| 36-item Short Form Health Survey | Change from baseline 36-item Short Form Health Survey scores at 1 month. | This questionnaire contains 9 parts: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health and Reported Health Transition. |
Countries
China
Contacts
Primary ContactYulan Ren, PhD
Backup ContactYiwei Zeng, M.D
Outcome results
None listed